|
業務類別
|
Biotechnology |
|
業務概覽
|
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed toaddress neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform. |
| 公司地址
| 1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT |
| 電話號碼
| +1 617 468-5770 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.centessa.com |
| 員工數量
| 118 |
| Mr. Raphael Deferiere, C.P.A. |
Chief Accounting Officer |
-- |
29/04/2026 |
| Dr. Gregory M. Weinhoff, M.B.A.,M.D. |
Chief Business Officer |
-- |
29/04/2026 |
| Ms. Karen Anderson |
Chief People Officer |
-- |
29/04/2026 |
| Dr. Mario Alberto Accardi, PhD |
Chief Executive Officer and Director |
-- |
29/04/2026 |
| Dr. Steven Kanes, M.D. |
Chief Medical Officer and Head of R&D |
-- |
29/04/2026 |
| Mr. John Crowley |
Chief Financial Officer |
美元 534.63K |
29/04/2026 |
| Mr. Iqbal Hussain |
General Counsel, Company Secretary, Chief Legal and Compliance Officer |
美元 519.03K |
29/04/2026 |
| Ms. Tia Bush |
Chief Technology and Quality Officer |
-- |
29/04/2026 |
|
|
| Dr. Mary Lynne Hedley,PhD |
Independent Director |
29/04/2026 |
| Dr. Mario Alberto Accardi, PhD |
Chief Executive Officer and Director |
29/04/2026 |
| Dr. Francesco De Rubertis, PhD |
Non-Executive Chairman of the Board |
29/04/2026 |
| Dr. Samarth Kulkarni, PhD |
Independent Director |
29/04/2026 |
| Dr. Arjun Goyal, M.B.A.,M.D.,M.Phil |
Independent Director |
29/04/2026 |
| Dr. Brett Zbar, M.D. |
Independent Director |
29/04/2026 |
| Ms. Carol Stuckley, M.B.A. |
Independent Director |
29/04/2026 |
| Dr. Mathias Hukkelhoven, PhD |
Independent Director |
29/04/2026 |
|
|
|
|
